Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its entry into an agreement with Pharmaseed Ltd., Israel’s largest GLP-certified pre-clinical contract research organization. Under the terms of this agreement, the Pharmaseed development team will now play a key role in the ongoing development of InMed’s lead compound, INM-750, which is a proprietary, topical cannabinoid product candidate that’s currently being studied as a therapy in epidermolysis bullosa and other potential dermatological and wound-healing applications. “This agreement with Pharmaseed now adds one of Israel’s leading formulation development teams to our efforts and represents an important strategic relationship as we move INM-750 towards our first clinical trial,” Eric A. Adams, CEO of InMed, noted in the news release. Moving forward, Pharmaseed will be tasked with developing a final formulation of INM-750 for continued R&D efforts, including IND-enabling pharmacology and toxicology studies, as well as subsequent clinical studies.
To view the full press release, visit http://dtn.fm/1gZW0
Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.